GNPX Genprex, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
19:37
Jan 16
Jan 16
Long tiny GNPX on trial-success optionality
Author is long Genprex, a small Austin-based pre-clinical/early clinical gene therapy company developing cancer and diabetes treatments via licensing deals with MD Anderson and other institutions. The mechanism is that Genprex coordinates clinical trials, FDA relations and patents around scientists' work, and promising animal results are now transitioning to human trials. With a tiny ~$7M market cap and ~2.2M share float, even modest phase 1/phase 2 success could re-rate the company into the hundreds of millions. The author explicitly acknowledges the low probability of success as the main risk.
HIGH
About GNPX Investor Commentary
Across the available history and selected sources, Buzzberg tracks GNPX (Genprex, Inc.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/realHarryGelb.